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Abstract 27 
Bi-layered hydroxypropylmethylcellulose and Eudragit based films were formulated as 28 
potential ocular drug delivery systems using chloramphenicol as a model antibiotic. Films were 29 
plasticized with polyethylene glycol 400 present in the Eudragit layer or both Eudragit and 30 
hydroxypropylmethylcellulose layers, and loaded with chloramphenicol (0.5% w/v in solution) 31 
in the hydroxypropylmethylcellulose layer. The weight, thickness and folding endurance 32 
optimized formulations were measured and further characterized for transparency, tensile, 33 
mucoadhesive, swelling and in vitro drug dissolution properties. The physical form of 34 
chloramphenicol within the films was evaluated using differential scanning calorimetry (DSC), 35 
and X-ray diffraction (XRD), complimented with scanning electron microscopy and energy 36 
dispersive X-ray spectroscopy. Fourier transform infrared spectroscopy was used to assess the 37 
interactions between the drug and the film components and confirm chloramphenicol’s 38 
presence within the sample. Optimum films showed high transparency (≥ 80% transmittance), 39 
ease of peeling from Petri dish and folding endurance above 250. Average thickness was lower 40 
than contact lenses (0.4 - 1mm), confirming them as thin ocular films. The tensile properties 41 
showed a good balance between toughness and flexibility and mucoadhesivity showed that 42 
they could potentially adhere to the ocular surface for prolonged periods. The drug loaded films 43 
showed swelling capacity which was greater than 300% of their original weight. The physical 44 
form of chloramphenicol within the films was amorphous (DSC and XRD) whilst in vitro drug 45 
dissolution showed sustained drug release from the films for four hours, before complete 46 
erosion. The chloramphenicol loaded films represent a potential means of treating common eye 47 
infections. 48 
 49 
Keywords: Antibacterial, bi-layered films, mucoadhesion, in vitro drug release, ocular 50 
delivery, plasticizer. 51 
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1 Introduction 52 
Vision provides 90% of the information within our surrounding environment, with 53 
considerable physiological importance including differentiation between light, shape and 54 
colour, spatial orientation, equilibrium and cortical tone [1]. Various conditions can affect the 55 
eyes and these are classified as periocular and intraocular, according to their location. 56 
Periocular conditions occur around the eye and can cause irritation to different parts of the eye. 57 
Common periocular diseases include blepharitis, conjunctivitis and chronic conditions caused 58 
by bacteria which can even lead to vision impairment [2]. Effective reduction of bacterial load 59 
is very important in the treatment of ocular diseases caused by infection.  60 
The development of ocular drug delivery systems is challenging because of the eyes’ 61 
complex anatomic structure and protective mechanisms which make it difficult to maintain an 62 
effective drug concentration over a prolonged period of time [3-8]. The eye is a very sensitive 63 
organ to debris, microorganisms and drugs and therefore, ocular drug delivery systems should 64 
be simple, non-invasive (to prevent irritation, inflammation, infection), maintain visual clarity, 65 
and enable the drug to penetrate the physiological eye barriers to reach the site of action [9]. 66 
Ocular drug delivery for treating conditions affecting the front of the eye depends on the 67 
corneal barrier and tear film. Apart from the physiological factors, there are also factors 68 
affecting formulation development, of ophthalmic preparations including osmolality, pH, 69 
surface tension and viscosity [10].  70 
Topical eye drops represent the most convenient formulation among patients, especially 71 
for conditions affecting the anterior segment of the eye. However, only 5% of the instilled dose 72 
can penetrate the ocular pre-corneal, dynamic and static barriers, while constant and prolonged 73 
drug release cannot be achieved [11]. Though gels and ointments can remain for relatively 74 
longer periods, they are quickly diluted by the tear fluid and leak out, therefore reducing 75 
bioavailability [12]. Ocular inserts such as films have been developed, which are expected to 76 
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maintain the drug on the eye surface for a relatively prolonged period better than drops, gels 77 
and ointments. These increase the contact time with the ocular surface and therefore prolong 78 
drug delivery, reduce systemic effects, improve patient compliance and increase bioavailability 79 
[12].  80 
Erodible films are made of polymers that can be natural, synthetic or semi-synthetic and 81 
that provide support for loaded drug. The polymers used need to be bio-compatible, safe, non 82 
reactive, stable and mucoadhesive, and release drug appropriately [13]. The drugs contained 83 
within the films are usually in the form of a dispersion within the matrix whilst maintaining 84 
film clarity [14]. Acyclovir, phenylepherine, diclofenac sodium, and antibiotics are examples 85 
of drugs that can be contained within the ocular inserts. All drugs need an appropriate balance 86 
between lipid and water solubility for effective corneal permeation. In addition, films generally 87 
need a plasticiser to improves their flexibility and reduce the chances of contact irritation due 88 
to britleness. 89 
In the present study, bi-layered erodible ocular films were prepared by solvent casting 90 
technique from solutions using hydrophobic Eudragit (EUD) and hydrophilic 91 
hydroxypropylmethylcellulose (HPMC). These polymers are safe and biocompatible, stable, 92 
mucoadhesive and provide sustained drug release in vitro, making them suitable for ocular 93 
delivery [15]. Polyethylene glycol 400 was used as a plasticiser in either the EUD or both 94 
polymeric layers to increase the flexibility of the films.  95 
Chloramphenicol (CHF) was used as model drug and exhibits broad-spectrum 96 
antibacterial activity [16] against Gram-positive bacteria (Staphylococcus aureus and, 97 
Streptococcus pyogenes) and Gram-negative bacteria Haemophilus influenza and Neisseria 98 
meningitides) common in ocular infections such as conjunctivitis [17]. Due to its high 99 
lipophilicity, CHF can easily penetrate the ocular barriers, and therefore very effective against 100 
ocular infections [17] However, its high lipid solubility facilitates easy absorption into the 101 
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systemic circulation and side effects such as aplastic anaemia can occur with prolonged 102 
exposure. Therefore, CHF is safely and efficiently used in eye drops at of 0.5% w/v 103 
(approximately 5000µg/ml) this dose was employed in this study [18]. The MIC values of CHF 104 
against the above organisms range from 0.25 - 128µg/ml [19] which is far lower than the dose 105 
used in this study. Because the residence time of eye drops on the cornea is poor, the use of the 106 
0.5% CHF dose within a mucoadhesive film which can prolong retention on the cornea and 107 
control drug release, is expected to overcome limitation of the former. Further, a more gradual 108 
release of CHF which prevents frequent administration, will reduce the incidence of side effects 109 
associated with CHF. 110 
 111 
2 Experimental 112 
2.1 Materials 113 
Eudragit S100 (EUD) was obtained from Degussa (Germany), 114 
hydroxypropylmethylcellulose – HPMC (Methocel™ K100 Premium) was a gift from 115 
Colorcon Limited (Dartford, UK). PEG, methanol, absolute ethanol, acetone, isopropyl 116 
alcohol, acetonitrile (HPLC grade) and phosphoric acid (HPLC grade) were supplied from 117 
Fisher Scientific, (Leicestershire, UK). Chloramphenicol was obtained from Sigma-Aldrich 118 
(Gillingham, UK). Sodium chloride, potassium chloride, sodium phosphate dibasic anhydrous 119 
(99+ % extra pure) and potassium phosphate dibasic anhydrous (99+ % extra pure) were all 120 
obtained from Acros Organics Ltd (New Jersey, USA).  121 
 122 
2.2 Film formulation development    123 
Different ratios of EUD to HPMC were weighed and dissolved in different mixtures of 124 
water with acetone, isopropyl alcohol, ethanol and methanol to obtain the polymeric solutions. 125 
However, none of the mixtures resulted in a completely clear film due to the poor water 126 
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solubility of EUD. The development of a completely clear EUD film was therefore achieved 127 
for a 2% w/v solution by dissolving the polymer in a mixture of acetone and isopropyl alcohol 128 
(ratio 3:2). HPMC only solution (2% w/v) was obtained by dissolving the required amount of 129 
polymer in deionised water. Bi-layered blank (BLK) films were subsequently prepared using 130 
the two 2% w/v (HPMC and EUD) solutions.   131 
Table 1 Preparation of (a)  solutions (2% w/v) required for BLK HPMC-EUD and (b)  132 
solutions (2% w/v) required for DL HPMC-EUD; bi-layered film formation. 133 
(a)  134 
EUD film  
 Polymer (g) PEG (g) Acetone (ml) Isopropyl 
alcohol (ml) 
EUD 1 2.007 2.001 60 40 
EUD 2 2.005 1.001 60 40 
HPMC film  
 Polymer (g) PEG used (g) CHF (g) Deionized 
water (ml) 
HPMC 1 2.002 - - 100 
HPMC 2 2.005 1.002 - 100 
 135 
(b) 136 
 137 
EUD film 
  Polymer (g) PEG (g) Acetone (ml) Isopropyl 
alcohol (ml) 
EUD 3 2.007 2.001 60 40 
EUD 4 2.001 1.002 60 40 
HPMC films 
  Polymer (g) PEG (g) CHF (g) Deionised 
water (ml) 
HPMC 3 2.000 - 0.50 100 
HPMC 4 2.004 1.001 0.50 100 
 138 
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Subsequently, 10g of the HPMC solution was poured onto the water insoluble EUD 139 
films and left to dry at room temperature for a further 24 hours to obtain the final bi-layered 140 
film. The drug loaded (DL) bi-layered films were obtained as above but with CHF (0.5% w/v) 141 
loaded in the HPMC solution before pouring on the BLK EUD film. For plasticised films, PEG 142 
(1.0% w/v) was added into either the EUD only or split between EUD (0.5% w/v) and HPMC 143 
(0.5% w/v) solutions. After preparation, 10g of EUD solution was poured into glass a Petri dish 144 
(82mm diameter) and left at room temperature for 24 hours to obtain the first film layer. The 145 
BLK (HPMC-EUD-PEG & HPMC-PEG-EUD-PEG) and DL (HPMC-CHF-EUD-PEG & 146 
HPMC-PEG-CHF-EUD-PEG) films (Table 1) were peeled from the Petri dish, visually 147 
examined for any physical defects (e.g. patches, scratches, cracks and tears) and suitable films 148 
stored in desiccators over silica until ready for use.  149 
 150 
2.3 Physical measurements  151 
2.3.1 Film thickness and weight  152 
Three film samples (n = 3) from each formulation were cut into 20 x 20mm2  strips, individually 153 
weighed using a digital  balance and average weight per mm2 calculated. Thickness was 154 
measured using a Metric micrometre screw gauge at five different locations i.e. four corners 155 
and middle and the average thickness calculated [20]. 156 
 157 
2.3.2 Transparency test  158 
Light transmittance was measured using a spectrophotometer (Model U-2900) set between the 159 
UV and IR range (300-1100nm). A 40 x 10mm2 strip was cut from each formulation and 160 
introduced into the spectrophotometer cell and percentage transmittance measured at a scan 161 
speed of 400nm/min.   162 
  163 
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2.3.3 Folding endurance  164 
A whole film removed from the Petri dish was used. Folding endurance was measured by 165 
repeatedly folding the film longitudinally at the same place until it broke [21], but no more 166 
than 250 times and recorded.  167 
 168 
2.4.1 Texture analysis 169 
2.4.1 Mechanical (tensile) properties 170 
The tensile properties (% elongation at break, tensile strength and elastic modulus) were 171 
measured using a TA.HD.plus Texture Analyser (Stable Micro Systems, Surrey, UK) equipped 172 
with a 5kg load cell. Films were cut into 50 x 10mm2 rectangular strips and their thickness 173 
measured. Each strip was held between the tensile grips of a texture analyser positioned 30mm 174 
apart. The strips were pulled using a trigger force of 0.09N at a crosshead speed of 0.1mms-1 175 
until they broke. The tensile properties were calculated using equations 1 - 3. 176 
      177 
𝑇𝑒𝑛𝑠𝑖𝑙𝑒 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ =  
𝐹𝑜𝑟𝑐𝑒 𝑎𝑡 𝑓𝑎𝑖𝑙𝑢𝑟𝑒
𝑐𝑟𝑜𝑠𝑠−𝑠𝑒𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑖𝑙𝑚
  Equation (1) 178 
 179 
 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑒𝑙𝑜𝑛𝑔𝑎𝑡𝑖𝑜𝑛 𝑎𝑡 𝑏𝑟𝑒𝑎𝑘 =  
𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒 𝑖𝑛 𝑙𝑒𝑛𝑔𝑡ℎ 𝑎𝑡 𝑏𝑟𝑒𝑎𝑘
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑓𝑖𝑙𝑚 𝑙𝑒𝑛𝑔𝑡ℎ
 × 100  Equation (2) 180 
 181 
𝐸𝑙𝑎𝑠𝑡𝑖𝑐 𝑚𝑜𝑑𝑢𝑙𝑢𝑠 =
𝑆𝑙𝑜𝑝𝑒 𝑜𝑓 𝑠𝑡𝑟𝑒𝑠−𝑠𝑡𝑟𝑎𝑖𝑛 𝑐𝑢𝑟𝑣𝑒
𝐹𝑖𝑙𝑚 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 × 𝐶𝑟𝑜𝑠𝑠 ℎ𝑒𝑎𝑑 𝑠𝑝𝑒𝑒𝑑
  Equation (3)  182 
 183 
2.4.2 In vitro mucoadhesion  184 
Each formulation was cut into four 10 x 10mm2 strips and attached onto the adhesive 185 
probe of a texture analyser equipped with a 5kg load cell, using double-sided adhesive tape. A 186 
model mucosa substrate in a Petri dish (86mm diameter), formed from a 6.67% w/v gelatine 187 
solution, allowed to set to form a solid gel, was equilibrated by spreading 20μl PBS solution 188 
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(pH 7.4) over its surface to simulate the ocular mucosa. The film attached to the probe was 189 
pressed onto the gelatine surface at a force of 0.5N, for 120 seconds (to allow proper contact 190 
with the gelatine layer) and detachment initiated [22]. The mucoadhesion strength was 191 
measured as the maximum force (Fmax) required for detaching the sample from the gelatine 192 
surface [23]. 193 
 194 
2.5 Scanning electron microscopy (SEM) 195 
SEM was used to analyse the surface morphology of the BLK and DL bi-layered films. 196 
Two small strips (0.5 x 0.5cm2) were cut from each film, attaching to a sample holder and 197 
coating with chromium to make them conductive and protect from heat. Both EUD and HPMC 198 
layers were analysed, to observe differences in morphology. The images were acquired using 199 
a Hitachi SU8030 scanning electron microscope with electronic beam voltage of 1.0kV, 200 
working distance of 8mm at different magnifications (x 250, 1000, 5000 and 10000).  201 
 202 
2.6 Analytical characterisation 203 
2.6.1 Attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy  204 
FTIR spectroscopy was used to analyse the presence of CHF in the DL films as well as 205 
the chemical interactions between the drug and the polymers. Testing was performed on a 206 
Perkin Elmer ATR-FTIR machine (Model Spectrum Two), at a wavelength between 450 and 207 
4000cm-1. The BLK and DL films, and starting materials were analysed. Prior to sample 208 
analyses, a background scan was performed and subtracted from all sample spectra.  209 
  210 
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2.6.2 Differential scanning calorimetry (DSC) 211 
DSC was used to assess the thermal behaviour of the BLK and DL films, and pure CHF. 212 
A small sample (2-5mg) was placed into a 40µl aluminium pan and sealed hermetically. The 213 
samples were heated between 25°C and 250°C at a rate of 10°C/min.  214 
 215 
2.6.3 X-ray diffraction (XRD) 216 
XRD was used to determine the physical form of BLK and DL films and CHF. The films 217 
were cut into six pieces and placed on top of each other in the transmitter holder. The samples 218 
were analyzed at an angular range of 4-45° 2θ, rotation of 15rpm and 0.6mm exit slit at 219 
increments of 0.02° 2θ [24]. 220 
 221 
2.6.4 Energy dispersive x-ray (EDX) spectroscopy  222 
A Hitachi SU8030 SEM equipped with a Thermo Fisher Scientific EDX was used to 223 
analyse the energy spectrum of the samples. The analysis was performed at an accelerating 224 
voltage of 8kV, working distance of 8mm and magnification of x9020, in order to determine 225 
the chlorine atoms present on the surface of the DL films and therefore demonstrate the 226 
distribution of CHF. 227 
 228 
2.7 Swelling capacity 229 
Swelling test was carried out to measure the swelling capacity of the optimum BLK and 230 
DL films. The films were cut into 20 x 20mm2 square strips and weighed accurately. Each strip 231 
was immersed into a Petri dish containing 5ml PBS solution at pH 7.4 and incubated at 232 
37±0.5°C [25]. At specific time intervals (10 minutes), the films were removed, blotted 233 
carefully with tissue paper to remove the excess PBS solution and accurately weighed. Then 234 
5ml of PBS solution was added to the previously swollen film and the procedure repeated till 235 
11 
 
no more increase in weight was observed. The swelling capacity (QS) was calculated for each 236 
time point using equation 4.  237 
    Equation (4) 238 
 Where, Wt is the weight of the swollen sample and W0 is the weight of the dried film.  239 
 240 
2.8 In vitro drug dissolution studies  241 
Prior to drug dissolution studies, HPLC was performed on an Agilent 1200 instrument, 242 
equipped with an auto sampler, using a 150mm × 4.6mm × 5μm column. The mobile phase 243 
comprised acetonitrile, deionised water and phosphoric acid – in volume ratio of 65: 35: 0.1 244 
with flow rate of 1.0ml/min and detection wavelength set at 280nm. Initially, standard solutions 245 
0.05, 0.10, 0.15, 0.20 and 0.25mg/ml of CHF in PBS solution (pH 7.4) were used to plot a 246 
calibration graph (R2 = 0.997) and used to calculate % drug release. For the drug dissolution 247 
studies, each DL film was cut into 20 × 20mm2 strips, weighed and placed in 20ml PBS, in a 248 
Petri dish. At pre-determined time intervals (0, 15, 30, 45, 60, 90, 120, 150, 180, 240 and 300 249 
minutes), 1.0ml aliquots were removed from each Petri dish and replaced with 1.0ml of fresh 250 
medium. The sampled solutions were analysed by HPLC as above.  251 
 252 
3 Results and discussion 253 
Ocular drug delivery systems need to possess functional characteristics such as being simple, 254 
non-invasive, maintaining visual clarity, allowing prolonged residence of the drug on the eye, 255 
to penetrate the physiological eye barriers and reach the site of action [9].  256 
 257 
3.1 Formulation development and optimisation 258 
Bi-layered, erodible HPMC and EUD films containing CHF were successfully 259 
developed and tested. These two polymers are well characterised for safety and 260 

Qs 
Wt W0
W0
100
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biocompatibility and known to be stable under normal processing and storage conditions. The 261 
2% w/v EUD and HPMC solutions used to prepare films were easy to handle and no heat was 262 
required during their formation. EUD only films were too thin, and difficult to remove from 263 
the Petri dish, but the addition of an HPMC solution layer on top of the EUD film led to the 264 
formation of a bi-layered film that was easy to peel from the Petri dish. Unplasticised films 265 
were brittle and addition of PEG made them more flexible and transparent. Figure 1 shows 266 
digital images of the four optimum bi-layered (two BLK and two DL) formulations selected 267 
for further testing. 268 
 269 
3.2 Physical measurements  270 
3.2.1 Thickness and film weight 271 
The thickness and weight of the optimized BLK and DL HPMC-EUD-PEG- and HPMC-PEG-272 
EUD-PEG were measured. The average thickness of the films was between 12 and 17μm, 273 
which classifies them as thin ocular films, and expected to be comfortable to the eyes Error! 274 
Reference source not found.. Further, the weight/mm2 increased as more components (PEG 275 
and CHF) were added to the HPMC solution layer. The starting weight/mm2 for the BLK 276 
HPMC-EUD-PEG film was 14.5, which increased by 15.51% after the addition of PEG within 277 
the HPMC layer, 6.89% after the addition of drug and by 29.31% after the addition of both 278 
plasticiser and drug.  279 
 280 
3.2.2 Transparency test 281 
An effective ocular formulation is expected not to interfere with sight and vision of the patient 282 
to avoid non-compliance [27], therefore in addition to visual observation, transmittance was 283 
recorded to determine the transparency of the BLK and DL films. Within the visible spectrum 284 
(400 and 700nm), the light transmittance of all samples was above 80% and no major peak was 285 
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present within this range. The BLK and DL films with only the EUD layer plasticised (HPMC-286 
EUD-PEG and HPMC-CHF-EUD-PEG respectively) had approximately 80% light 287 
transmission, while the BLK and DL films with both layers plasticised (HPMC-PEG-EUD-288 
PEG and HPMC-PEG-CHF-EUD-PEG) was higher at 87.5%. Therefore, drug loading did not 289 
appear to significantly affect the clarity of the samples, whilst the addition of PEG in the 290 
formulation of both HPMC and EUD solutions led to a higher transparency, making plasticised 291 
films more suitable for ocular drug delivery. Though the films were clear when observed 292 
visually, further improvement of transparency to 96%, to match that of contact lenses, will be 293 
ideal Error! Reference source not found.. This may be achieved by the addition of more 294 
plasticiser in both polymeric layers.   295 
 296 
3.2.3 Folding endurance 297 
Optimized BLK and DL films were longitudinally folded at the same place to assess their 298 
resistance to folding during repeated handling. None of the films broke after being folded 250 299 
times, implying good resistance to handling, which is an essential functional characteristic for 300 
any ocular drug delivery system which must be safe to the patient if it needs to be removed and 301 
reinserted [29] while remaining intact. The folding endurance is also an indication of 302 
mechanical resistance to deformation, however, to more accurately determine the mechanical 303 
properties of the films, tensile properties were measured using a texture analyser. 304 
 305 
3.3 Texture analysis 306 
3.3.1 Mechanical (tensile) properties 307 
The tensile properties (tensile strength, elastic modulus and % elongation at break) of the BLK 308 
and DL EUD-HPMC films are shown in Figure 2a. All the films had % elongation values 309 
within the reported ideal range of 30 – 50% [30] where films are neither too brittle nor too 310 
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sticky, which is important to avoid breaking or difficulty in handling. The highest value for 311 
elastic modulus was achieved by the BLK HPMC-EUD-PEG films. The values of elastic 312 
modulus showed that addition of PEG in both EUD and HPMC layers made the films more 313 
flexible, which was also confirmed by the higher values of % elongation at break for these 314 
films. Addition of CHF made them more flexible with HPMC-PEG-CHF-EUD-PEG having 315 
better tensile properties compared to HPMC-CHF-EUD-PEG film due to the addition of PEG 316 
in both polymeric layers of the former. This resulted in better elasticity, decreased stiffness and 317 
brittleness, making it more suitable for ocular drug delivery as its flexibility makes it less likely 318 
to cause contact irritation, therefore potentially providing better patient compliance [31]. 319 
Plasticisers generally act by interrupting the intermolecular interactions between polymer 320 
chains and increasing the specific volume, thus increasing their molecular mobility and 321 
therefore making them more flexible [32]. 322 
 323 
3.3.2 In vitro mucoadhesion studies 324 
Mucoadhesion strength was measured using the gelatine layer, to simulate bioadhesion of the 325 
films to the ocular surface. As shown in Figure 2b, the highest detachment force necessary to 326 
remove the film from the gelatine layer was observed for BLK and DL films with only the 327 
EUD layer plasticised (HPMC-EUD-PEG and HPMC-CHF-EUD-PEG). This is interesting and 328 
appears to confirm the swelling capacity results below. This is because the initial stages of 329 
mucoadhesion involve polymer hydration and swelling which enhance the inter-diffusion 330 
process, allowing physical entanglement and enhanced surface availability for hydrogen 331 
bonding and electrostatic interaction between the polymeric chains and the model mucosal 332 
substrate. 333 
Overall, the average detachment force required for all samples was higher than the force 334 
(0.2N) required by the eyelids to blink, implying that the formulated films will not be easily 335 
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dislodged by blinking. In addition, due to their thin nature, the hydrated ocular films are 336 
expected to be comfortable to patients though this will need to be confirmed in an in vivo study.  337 
3.4 Scanning electron microscopy (SEM) 338 
The SEM images for CHF confirmed its crystalline structure, as shown in Figure 3a. 339 
The images obtained from the surface of both sides of the BLK films, shown in the Figure 3 (b 340 
& c) revealed the presence of flat and irregular three-dimensional crystals on the surface of the 341 
HPMC layer. These may be due to the incomplete dissolution of HPMC in water, or the slow 342 
drying process at room temperature, which allowed some of the dissolved polymer to 343 
recrystallize on the surface as HPMC is known to be semi-crystalline. The EUD layer was 344 
smooth, possibly due to the complete dissolution of the polymer in organic solvents during 345 
formulation. The SEM images obtained for the surface of the DL HPMC-EUD films shown in 346 
Figure A1 (d – g) of the appendix revealed the presence of needle shaped structures, which 347 
may be CHF crystals. The EUD layer remained smooth, confirming the possibility of complete 348 
dissolution of EUD within the acetone and isopropyl alcohol.  349 
SEM of the HPMC layer of DL films appears to contradict the results from DSC and 350 
XRD testing, which showed that the drug was possibly changed to its amorphous form or 351 
molecularly dispersed during the formulation process. Further analysis of the needle-shaped 352 
crystals was therefore necessary in order to determine whether they represent another 353 
crystalline form of CHF, and this was done using EDX analysis. 354 
 355 
3.5 Analytical characterisation 356 
3.5.1 Fourier transform infrared spectroscopy (FTIR) 357 
The FTIR spectra obtained for the BLK and DL films are shown in Figure A2 of the 358 
appendix, showing similar peak patterns, due to similar formulation components (HPMC and 359 
EUD).  The peak present around 3500cm-1 is attributed to the presence of the OH group of 360 
16 
 
HPMC. The C=O group of EUD was observed around 1750cm-1 and the peaks present around 361 
1000cm-1 is due to the presence of the C-O bond, from HPMC and EUD. The addition of PEG 362 
in both polymeric layers and of CHF resulted in additional sharp peaks.  A peak was observed 363 
at 1522cm-1 for only DL films, and attributed to the aromatic ring present in CHF, suggesting 364 
little or no interaction between the drug and the polymer within the HPMC layer.  365 
 366 
3.5.2 Differential scanning calorimetry (DSC) 367 
Figure 4 shows the DSC thermograms obtained for CHF and BLK and DL bi-layered 368 
HPMC-EUD films. The sharp peak for pure CHF (Figure 4a) revealed its crystalline nature and 369 
its melting point matched that previously reported at 159.06°C [33]. The thermograms for the 370 
BLK and DL films (Figure 4b) showed no obvious sharp peaks expected for crystalline 371 
materials, suggesting that CHF was converted to the amorphous form or molecularly dispersed 372 
within the polymeric matrix. It is also possible that the amount of CHF present in the small 2-373 
5mg sample analysed was too low to allow detection. The BLK films showed a broad 374 
endothermic peak beyond 210°C which was not found in the corresponding DL films. This 375 
might relate to the presence of free PEG which was not available in the DL films due to the 376 
presence of CHF.  377 
 378 
3.5.3 X-ray diffraction (XRD) 379 
 XRD diffractograms for the BLK and DL films are shown in Figure 5a. The 380 
diffractogram obtained for CHF (data not shown) clearly showed its crystalline nature with 381 
sharp peaks comparable with reference peaks in the instrument database. For the BLK HPMC-382 
EUD film samples, the diffractograms showed a typically amorphous pattern with a broad peak. 383 
The analysis of the DL HPMC-EUD films gave similar results, confirming the DSC results that 384 
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the drug was possibly changed to its amorphous form or molecularly dispersed during film 385 
formulation.  386 
  387 
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3.5.4 Energy dispersive x-ray spectroscopy (EDX) 388 
EDX spectroscopy confirmed the presence of chlorine and nitrogen atoms within pure 389 
CHF. However, it did not confirm the presence of the drug in the DL film, as no chlorine or 390 
nitrogen atoms were detectable (Figure 5b). This may be due to the low amount of CHF within 391 
the small section of the films cut for analysis, which was therefore not detectable, or possibly 392 
due to the fact that the molecular dispersion of CHF within the polymer matrix caused the 393 
chlorine and nitrogen atoms to be shielded by significantly high amounts of polymer chains 394 
surrounding them.  395 
 396 
3.6 Swelling capacity 397 
The initial hydration and swelling of a film are important functional characteristics as they 398 
significantly affect other important properties such as mucoadhesion and drug release [34]. The 399 
results (Figure 6a) showed that HPMC-CHF-EUD-PEG film hydrated and swelled most 400 
rapidly, showing a maximum swelling of 557%. The swelling capacity for the DL films 401 
(HPMC-PEG-CHF-EUD-PEG and HPMC-CHF-EUD-PEG) were higher compared to the 402 
corresponding BLK films. The higher swelling capacity of DL films can be attributed to the 403 
release of CHF from the HPMC layer which allowed further ingress of more fluid into the 404 
swollen matrix. Comparing the two DL films, the formulation with both layers plasticised 405 
remained intact for a longer period of time, representing an optimum ocular drug delivery 406 
system. In addition, all films completely disintegrated after 270 minutes, meaning that they are 407 
erodible and will be able to provide sustained drug release for at least 4 hours.  408 
 409 
3.7 In vitro drug dissolution studies 410 
Drug dissolution profiles of both DL HPMC-EUD films loaded with CHF was 411 
monitored using PBS (pH 7.4), to simulate the ocular tear fluid. Both DL films had similar 412 
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drug dissolution profiles (Figure 6b), showing a biphasic release, with an initial phase where 413 
approximately 60% of the drug was released from the matrix within the first two hours, 414 
followed by a second sustained release phase. The initial 60% released corresponds to 2273µg 415 
of CHF which is significantly higher than the MIC of the drug required to kill bacteria which 416 
cause common eye infections such as conjunctivitis. However, this will require confirmation 417 
in a future in vitro antibacterial assay. Further, up to 70% of the drug will be released from the 418 
polymeric matrix before the film completely erodes. This bi-phasic release make the films 419 
suitable ocular drug delivery systems offering sustained release up to 4 hours, until they 420 
completely erode, and therefore more efficient against bacteria in comparison with 421 
conventional eye drops and ointments. The plasticiser in both polymeric layers was associated 422 
with a slightly reduced drug release, due mainly to the interaction between PEG and the 423 
polymers suggesting that it might be better to have the PEG present in just one layer.  424 
Other studies [35, 36] have reported the use of drug-soaked soft contact lenses to deliver 425 
appropriate amounts of drug, however, though these offer an improvement over eye drops, they 426 
have limitations. Firstly, drug loading capacity is dependent on equilibrium drug solubility 427 
within the lens. Drug diffusion from the stock solution does not happen instantly and requires 428 
several hours for complete saturation. Further, drug concentration in the original solution must 429 
be higher than the final soaked lens to maintain effective diffusion gradient, resulting in drug 430 
being wasted and therefore uneconomical [37]. Finally, the lens will require re-soaking in drug 431 
solution after a short period. On the other hand, the erodible films degrade slowly and therefore 432 
can remain on the eye for four hours but without the need for removal. More advanced options 433 
include imprinted and liposome loaded lenses or films for sustained drug delivery, however, 434 
these are more complex to formulate and more likely to be significantly more expensive than 435 
eye drops. The bi-layered films are are simple and cost effective and therefore an ideal 436 
alternative to eye drops. 437 
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4 Conclusion 438 
Bi-layered ocular films were successfully prepared using hydrophobic EUD and hydrophilic 439 
HPMC. The HPMC-CHF-EUD-PEG film was the most suitable for ocular drug delivery, 440 
having good physicochemical properties, providing sustained drug release, expected to 441 
maintain the drug on the eye surface for a relatively prolonged period and also expected to 442 
completely erode. The DL films have great potential as ocular drug delivery system for treating 443 
common eye infections as they are expected to be easy to use, comfortable, and efficient and 444 
their removal would not be necessary. However, an antibacterial study of these films is 445 
essential to determine the efficiency of CHF against bacteria that affect the eyes. 446 
 447 
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Figure legends  553 
Figure 1: Digital images of optimum films formulated (a) BLK HPMC-EUD-PEG (b) BLK 554 
HPMC-PEG-EUD-PEG (c) DL HPMC-CHF-EUD-PEG (d) DL HPMC-PEG-CHF-EUD-555 
PEG. 556 
 557 
Figure 2: (a) Tensile profiles showing average (± SD, n = 3) % elongation at break, tensile 558 
strength and elastic modulus for BLK (HPMC-EUD-PEG & HPMC-PEG-EUD-PEG)  and 559 
DL (HPMC-CHF-EUD-PEG & HPMC-PEG-CHF-EUD-PEG) films and (b) Mucoadhesion 560 
profiles (± SD, n = 3) showing average detachment force for both BLK and DL films. 561 
 562 
Figure 3: SEM images for (a) pure CHF, (b) HPMC layer of BLK HPMC-EUD-PEG films 563 
and EUD layer of BLK HPMC-EUD-PEG; bi-layer films [(the SEM images of DL films 564 
containing CHF are shown in supplementary data section (Figure A1)]  565 
 566 
Figure 4: DSC thermograms obtained for (a) pure CHF and (b) BLK (HPMC-EUD-PEG & 567 
HPMC-PEG-EUD-PEG) and DL (HPMC-CHF-EUD-PEG & HPMC-PEG-CHF-EUD-PEG) 568 
films. 569 
 570 
Figure 5: (a) XRD diffractograms for BLK (HPMC-EUD-PEG & HPMC-PEG-EUD-PEG) 571 
and DL (HPMC-CHF-EUD-PEG) films and (b) EDX results for CHF and DL HPMC-PEG-572 
CHF-EUD-PEG film. 573 
 574 
Figure 6: (a) Swelling profiles comparing swelling capacity for BLK (HPMC-EUD-PEG & 575 
HPMC-PEG-EUD-PEG) and DL (HPMC-CHF-EUD-PEG & HPMC-PEG-CHF-EUD-PEG) 576 
bi-layered films and (b) In vitro drug dissolution profiles (± SD, n = 3) of (a) DL HPMC-577 
CHF-EUD-PEG and DL HPMC-PEG-CHF-EUD-PEG films. 578 
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